To the Editor: The article by Fischl et al. (Oct. 11 issue)* is a very important contribution to the literature on the use of zidovudine in patients with the acquired immunodeficiency syndrome (AIDS). The data presented have already substantially affected the day-to-day care of patients with human immunodeficiency virus (HIV) infection. The study was designed to use an intention-to-treat analysis of the data. Was there a difference in the incidence of opportunistic infections and death between the standard-treatment group and the low-dose group when the results for those who remained on therapy were analyzed? This question is important, because patients.
ASJC Scopus subject areas